Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 34
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome

  • McMacken, Grace M.
  • Spendiff, Sally
  • Whittaker, Roger G.
  • O'Connor, Emily
  • Howarth, Rachel M.
  • Boczonadi, Veronika
  • Horvath, Rita
  • Slater, Clarke R.
  • Lochmüller, Hanns
The β-adrenergic agonists salbutamol and ephedrine have proven to be effective as therapies for human disorders of the neuromuscular junction, in particular many subsets of congenital myasthenic syndromes. However, the mechanisms underlying this clinical benefit are unknown and improved understanding of the effect of adrenergic signalling on the neuromuscular junction is essential to facilitate the development of more targeted therapies. Here, we investigated the effect of salbutamol treatment on the neuromuscular junction in the ColQ deficient mouse, a model of end-plate acetylcholinesterase deficiency. ColQ-/- mice received 7 weeks of daily salbutamol injection, and the effect on muscle strength and neuromuscular junction morphology was analysed. We show that salbutamol leads to a gradual improvement in muscle strength in ColQ-/- mice. In addition, the neuromuscular junctions of salbutamol treated mice showed significant improvements in several postsynaptic morphological defects, including increased synaptic area, acetylcholine receptor area and density, and extent of postjunctional folds. These changes occurred without alterations in skeletal muscle fibre size or type. These findings suggest that β-adrenergic agonists lead to functional benefit in the ColQ-/- mouse and to long-term structural changes at the neuromuscular junction. These effects are primarily at the postsynaptic membrane and may lead to enhanced neuromuscular transmission., Guarantors of Brain/Association of British Neurologists (Clinical Research Training Fellowship to G.M.); Wellcome Trust (Pathfinder Award, 201064/Z/16/Z; Investigator Award 109915/Z/15/Z to R.H.); the Medical Research Council (Confidence in Concept fund to R.H., H.L. and S.S.; MR/N025431/1 to R.H.); Canadian Institute of Health Research (PJT 162265 to S.S. and H.L.); Newton Fund UK/Turkey (MR/N027302/1 to R.H.); European Research Council (309548 to R.H.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

COL4A1-related autosomal recessive encephalopathy in 2 Turkish children

  • Yaramis, Ahmet
  • Lochmüller, Hanns
  • Töpf, Ana
  • Sonmezler, Ece
  • Yilmaz, Elmasnur
  • Hiz, Semra
  • Yis, Uluc
  • Gungor, Serdal
  • Polat, Ayse Ipek
  • Edem, Pinar
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Yaramis, Aysenur
  • Horvath, Rita
  • Oktay, Yavuz
OBJECTIVE: This study presents the neurologic phenotypes of 2 brothers with a novel homozygous COL4A1 mutation that was identified in a large Turkish consanguineous cohort of neurogenetic diseases. METHODS: Whole-exome sequencing and bioinformatic analysis of consanguineous families with children affected by early-onset, neurogenetic disorders was performed using the RD-Connect Genome-Phenome Analysis Platform. We also performed clinical, EEG, and neuroimaging analyses in unaffected siblings and parents. RESULTS: We have identified a homozygous missense mutation in COL4A1 (p.Gly1278Ser, NM_001845.5:c.3832G>T) in 2 siblings affected by small vessel brain disease with periventricular leukoencephalopathy and ocular defects. Presenting symptoms included mild weakness, hemiparetic gait, pyramidal findings, and seizures, whereas their intellectual and behavioral functions were normal. Both parents and 5 of the siblings (3 boys and 2 girls) were heterozygous for the variant. They did not show any clinical or laboratory signs of small vessel disease. CONCLUSIONS: COL4A1 has previously been associated with dominant small vessel disease of the brain and other organs, manifesting with high penetrance in heterozygous mutation carriers. Our findings provide evidence that COL4A1-related encephalopathy can be inherited in an autosomal recessive manner, which is important for counseling, prognosis, and treatment. Genotype-phenotype correlations remain to be established., This study was supported by the Turkish Scientific and Research Council (TUBITAK) research grant 216S771 (A. Yaramis, S. Hiz, U. Yis, S. Gungor, and Y. Oktay). R. Horvath is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and the Newton Fund (UK/Turkey, MR/N027302/1)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O'Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant

  • Lochmüller, Hanns
  • Balaraju, Sunitha
  • Laurie, Steven, 1973-
  • Lochmüller, Hanns
Congenital myasthenic syndromes (CMS) are a clinically and genetically heterogeneous group of disorders caused by mutations which lead to impaired neuromuscular transmission. SLC25A1 encodes a mitochondrial citrate carrier, associated mainly with the severe neurometabolic disease combined D-2- and L-2-hydroxyglutaric aciduria (D/L-2-HGA). We previously reported a single family with a homozygous missense variant in SLC25A1 with a phenotype restricted to relatively mild CMS with intellectual disability, but to date no additional cases of this CMS subtype had been reported. Here, we performed whole exome sequencing (WES) in three additional and unrelated families presenting with CMS and mild intellectual disability to identify the underlying causative gene. The WES analysis revealed the presence of a homozygous c.740G>A; p.(Arg247Gln) missense SLC25A1 variant, the same SLC25A1 variant as identified in the original family with this phenotype. Electron microscopy of muscle from two cases revealed enlarged and accumulated mitochondria. Haplotype analysis performed in two unrelated families suggested that this variant is a result of recurrent mutation and not a founder effect. This suggests that p.(Arg247Gln) is associated with a relatively mild CMS phenotype with subtle mitochondrial abnormalities, while other variants in this gene cause more severe neurometabolic disease. In conclusion, the p.(Arg247Gln) SLC25A1 variant should be considered in patients presenting with a presynaptic CMS phenotype, particularly with accompanying intellectual disability., The project is supported by Newton fund under the governance of Academy of Medical Sciences. SB is a Newton International postdoctoral fellow (Ref no.NIF003/1002). RH was supported by the Medical Research Council (UK) [MR/N025431/1], the Wellcome Investigator fund [109915/Z/15/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the European Research Council [309548] and the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z]. RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the MRC Centre for Neuromuscular Diseases (G0601943), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council (G016354/1). HL is supported by a project grant of the Canadian Institutes of Health Research (CIHR, PJT 162265)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Severe neurodevelopmental disease caused by a homozygous TLK2 variant

  • Topf, Ana
  • Oktay, Yavuz
  • Balaraju, Sunitha
  • Yilmaz, Elmasnur
  • Sonmezler, Ece
  • Yis, Uluc
  • Laurie, Steven, 1973-
  • Thompson, Rachel
  • Roos, Andreas
  • MacArthur, Daniel G.
  • Yaramis, Ahmet
  • Güngör, Serdal
  • Lochmüller, Hanns
  • Hiz, Semra
  • Horvath, Rita
A distinct neurodevelopmental phenotype characterised mainly by mild motor and language delay and facial dysmorphism, caused by heterozygous de novo or dominant variants in the TLK2 gene has recently been described. All cases reported carried either truncating variants located throughout the gene, or missense changes principally located at the C-terminal end of the protein mostly resulting in haploinsufficiency of TLK2. Through whole exome sequencing, we identified a homozygous missense variant in TLK2 in a patient showing more severe symptoms than those previously described, including cerebellar vermis hypoplasia and West syndrome. Both parents are heterozygous for the variant and clinically unaffected highlighting that recessive variants in TLK2 can also be disease causing and may act through a different pathomechanism., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). The Broad Centre for Mendelian Genomics (UM1 HG008900) is funded by the National Human Genome Research Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) programme and the National Eye Institute. Data were analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy

  • van der Knoop, Marieke M.
  • Lochmüller, Hanns
  • Houlden, Henry
Data de publicació electrònica: 04-04-2022, Pathogenic variants in A Disintegrin And Metalloproteinase (ADAM) 22, the postsynaptic cell membrane receptor for the glycoprotein leucine-rich repeat glioma-inactivated protein 1 (LGI1), have been recently associated with recessive developmental and epileptic encephalopathy. However, so far, only two affected individuals have been described and many features of this disorder are unknown. We refine the phenotype and report 19 additional individuals harboring compound heterozygous or homozygous inactivating ADAM22 variants, of whom 18 had clinical data available. Additionally, we provide follow-up data from two previously reported cases. All affected individuals exhibited infantile-onset, treatment-resistant epilepsy. Additional clinical features included moderate to profound global developmental delay/intellectual disability (20/20), hypotonia (12/20), delayed motor development (19/20). Brain MRI findings included cerebral atrophy (13/20), supported by post-mortem histological examination in patient-derived brain tissue, cerebellar vermis atrophy (5/20), and callosal hypoplasia (4/20). Functional studies in transfected cell lines confirmed the deleteriousness of all identified variants and indicated at least three distinct pathological mechanisms: defective cell membrane expression (1), impaired LGI1-binding (2), and/or impaired interaction with the postsynaptic density protein PSD-95 (3). We reveal novel clinical and molecular hallmarks of ADAM22 deficiency and provide knowledge that might inform clinical management and early diagnostics., Funding: most families were collected as part of the SYNaPS Study Group collaboration funded by the Wellcome Trust and strategic award (Synaptopathies) funding (WT093205 MA and WT104033AIA). This study was also supported by JSPS/MEXT KAKENHI (Grants 19H03331, 19K22439 and 21K19390 to Y.F., Grant 19K16269 to Y.M., and Grants 20H00459 and 20H04915 to M.F.) and Japan Agency for Medical Research and Development (21wm0525022h0001 to Y.F.); intramural funding (fortüne) from the University of Tübingen (Grant 2545-1-0) and the Ministry of Science, Research and Art Baden-Württemberg to B.V. P.S. contributed to this work within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). T.B.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 418081722, 433158657. I.S.P., V.Y.V. are supported by the Government Assignment of the Russian Ministry of Health (#121061500066-2). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). S.H. is funded by TUBITAK (Turkish Scientific and Technological Research Council) Project number 216S771. R.H. is a Wellcome Trust Investigator (109915/Z/15/Z), who received support from the Medical Research Council (UK) (MR/N025431/1 and MR/V009346/1), the European Research Council (309548), the Newton Fund (UK/Turkey, MR/N027302/1), the Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily Foundation and an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A de novo CSDE1 variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents

  • Gangfuß, Andrea
  • Lochmüller, Hanns
  • Töpf, Ana
  • O'Hehir, Emily
  • Horvath, Rita
  • Kölbel, Heike
  • Schweiger, Bernd
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
CSDE1 encodes the cytoplasmic cold shock domain-containing protein E1 (CSDE1), which is highly conserved across species and functions as an RNA-binding protein involved in translationally coupled mRNA turnover. CSDE1 displays a bidirectional role: promoting and repressing the translation of RNAs but also increasing and decreasing the abundance of RNAs. Preclinical studies highlighted an involvement of CSDE1 in different forms of cancer. Moreover, CSDE1 is highly expressed in human embryonic stem cells and plays a role in neuronal migration and differentiation. A genome-wide association study suggested CSDE1 as a potential autism-spectrum disorder risk gene. A multicenter next generation sequencing approach unraveled likely causative heterozygous variants in CSDE1 in 18 patients, identifying a new autism spectrum disorder-related syndrome consisting of autism, intellectual disability, and neurodevelopmental delay. Since then, no further patients with CSDE1 variants have been reported in the literature. Here, we report a 9.5-year-old girl from a consanguineous family of Turkish origin suffering from profound delayed speech and motor development, moderate intellectual disability, neurologic and psychiatric symptoms as well as hypoplasia of corpus callosum and mildly reduced brain volume on brain magnetic resonance imaging associated with a recurrent de novo mutation in CSDE1 (c.367C > T; p.R123*) expanding the phenotypical spectrum associated with pathogenic CSDE1 variants., Funding: Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1) and the Lily Foundation and the Evelyn Trust. Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Molecular pathophysiology of human MICU1 deficiency

  • Kohlschmidt, Nicolai
  • Elbracht, Miriam
  • Czech, Artur
  • Häusler, Martin
  • Phan, Vietxuan
  • Töpf, Ana
  • Huang, Kai-Ting
  • Bartok, Adam
  • Eggermann, Katja
  • Zippel, Stephanie
  • Eggermann, Thomas
  • Freier, Erik
  • Groß, Claudia
  • Lochmüller, Hanns
  • Horvath, Rita
  • Hajnóczky, György
  • Weis, Joachim
  • Roos, Andreas
Aims: MICU1 encodes the gatekeeper of the mitochondrial Ca2+ uniporter, MICU1 and biallelic loss-of-function mutations cause a complex, neuromuscular disorder in children. Although the role of the protein is well understood, the precise molecular pathophysiology leading to this neuropaediatric phenotype has not been fully elucidated. Here we aimed to obtain novel insights into MICU1 pathophysiology. Methods: Molecular genetic studies along with proteomic profiling, electron-, light- and Coherent anti-Stokes Raman scattering microscopy and immuno-based studies of protein abundances and Ca2+ transport studies were employed to examine the pathophysiology of MICU1 deficiency in humans. Results: We describe two patients carrying MICU1 mutations, two nonsense (c.52C>T; p.(Arg18*) and c.553C>T; p.(Arg185*)) and an intragenic exon 2-deletion presenting with ataxia, developmental delay and early onset myopathy, clinodactyly, attention deficits, insomnia and impaired cognitive pain perception. Muscle biopsies revealed signs of dystrophy and neurogenic atrophy, severe mitochondrial perturbations, altered Golgi structure, vacuoles and altered lipid homeostasis. Comparative mitochondrial Ca2+ transport and proteomic studies on lymphoblastoid cells revealed that the [Ca2+ ] threshold and the cooperative activation of mitochondrial Ca2+ uptake were lost in MICU1-deficient cells and that 39 proteins were altered in abundance. Several of those proteins are linked to mitochondrial dysfunction and/or perturbed Ca2+ homeostasis, also impacting on regular cytoskeleton (affecting Spectrin) and Golgi architecture, as well as cellular survival mechanisms. Conclusions: Our findings (i) link dysregulation of mitochondrial Ca2+ uptake with muscle pathology (including perturbed lipid homeostasis and ER-Golgi morphology), (ii) support the concept of a functional interplay of ER-Golgi and mitochondria in lipid homeostasis and (iii) reveal the vulnerability of the cellular proteome as part of the MICU1-related pathophysiology., This study was supported by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung’ and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz-Research-Cluster (grant number: 031A360E). This work was also supported by a grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR and by an NIH grant (RO1 GM102724) to GH. The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 2012-305121 ‘Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)’. RH is a Wellcome Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Newton Fund (MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412) and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Metabolic shift underlies recovery in reversible infantile respiratory chain deficiency

  • Hathazi, Denisa
  • Lochmüller, Hanns
  • Horvath, Rita
Reversible infantile respiratory chain deficiency (RIRCD) is a rare mitochondrial myopathy leading to severe metabolic disturbances in infants, which recover spontaneously after 6-months of age. RIRCD is associated with the homoplasmic m.14674T>C mitochondrial DNA mutation; however, only ~ 1/100 carriers develop the disease. We studied 27 affected and 15 unaffected individuals from 19 families and found additional heterozygous mutations in nuclear genes interacting with mt-tRNAGlu including EARS2 and TRMU in the majority of affected individuals, but not in healthy carriers of m.14674T>C, supporting a digenic inheritance. Our transcriptomic and proteomic analysis of patient muscle suggests a stepwise mechanism where first, the integrated stress response associated with increased FGF21 and GDF15 expression enhances the metabolism modulated by serine biosynthesis, one carbon metabolism, TCA lipid oxidation and amino acid availability, while in the second step mTOR activation leads to increased mitochondrial biogenesis. Our data suggest that the spontaneous recovery in infants with digenic mutations may be modulated by the above described changes. Similar mechanisms may explain the variable penetrance and tissue specificity of other mtDNA mutations and highlight the potential role of amino acids in improving mitochondrial disease., RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust.
Repisalud
Publicación Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biodegradability of bio-based materials produced with dry heating treatment-modified cassava starch

  • La Fuente-Arias, Carla Ivonne
  • Atanazio-Silva, G.
  • Anjos, C.
  • Tadini, Carmen
[EN] Among the different types of starch modification that increase their performance, dry heating treatment (DHT) is a promising green technique that results in plastic materials with enhanced characteristics, mainly in their mechanical and barrier properties. The effect of this type of modification on its biodegradability and disintegration behavior has yet to be described in the literature. Therefore, this work aims to produce bio-based plastic with cassava starch previously modified by DHT and study its disintegration and biodegradation in compost media. The main results showed that all materials showed up to 80% and 90% biodegradation and disintegration, respectively, for all materials in 45 days. Moreover, higher rates of disintegration were visualized until day 7, as well as microbial growth and disappearance of functional groups, which is attributed to the highly hydrophilic nature of starch that facilitates the hydrolysis of the polymer in the early stages. In particular, the sheet submitted to DHT for 4 h showed higher rates. In this study was produced by extrusion bio-based plastic with cassava starch previously modified by dry heating treatment (DHT) technique, and the effect of this modification process on its biodegradability/disintegration behavior was evaluated. The main results revealed that all materials showed greater values of biodegradation and disintegration, while DHT affected the polymer structure and, thus, its biodegradability.image, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Grant/Award Number: 309548/2021; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant/Award Numbers: 2017/05307-8, 2016/12385-2
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Bio-Based Plastic Based on Ozonated Cassava Starch Produced by Extrusion

  • La Fuente-Arias, Carla Ivonne|||0000-0003-3435-8679
  • do Val Siqueira, Larissa
  • Augusto, Pedro Esteves Duarte
  • Tadini, Carmen C.
[EN] Green methods of modification, such as ozone, can bring new functionalities to starch. In this study, starch-based plastics were produced by extrusion, using cassava starch ozonated with a gas flow of 1 L min(-1) at a concentration of 41 mg O-3 L-1 resulting in doses of 78.9 and 145.3 mg O-3/g starch. Pre-mixes (starch, glycerol, and water) were processed in a co-rotating twin-screw extruder. The main results showed that ozonated sheet produced with the treatment of 78.9 mg O-3/g starch resulted in an increase in Young Modulus by 43% and a decrease in hydrophilicity by 37% in comparison to the native one. Conversely, treatment with 145.3 mg O-3/g starch did not increase the bio-based plastic mechanical properties or surface characteristics, showing a specific behavior tendency between ozonation and extrusion processes. The ozonation of starch showed to be an alternative for producing by extrusion bio-based plastics with enhanced properties, by selecting adequate processing conditions., The authors acknowledge the Sao Paulo Research Foundation (FAPESP) for the postdoctoral fellowship of CIA La Fuente (2017/05307-8), the Ph.D. scholarship of L Siqueira (2019/21700-7), and the project EMU 2016/12385-2; and the National Council for Scientific and Technological Development (CNPq, Brazil) for funding the project of CIA La Fuente (429043/2018-0) and the productivity grants of PED Augusto (310839/2020-3) and CC Tadini (309548/2021).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biodegradable polymers: A review about biodegradation and its implications and applications

  • La Fuente-Arias, Carla Ivonne|||0000-0003-3435-8679
  • Maniglia, Bianca Chieregato
  • Tadini, Carmen Cecília
[EN] Plastic waste pollution is a global environmental problem that could be solved by biodegradable materials. In addition, its biodegradability has been important for medical applications. In this way, the biodegradability performance has been investigated for different materials under diversified environmental conditions. In this context, this review shows the main up-to-date biodegradable polymers (from renewable sources and fossil-based), their structure and properties, and their biodegradability characteristics. Also, this review shows the effect of polymer properties and environmental conditions on biodegradability, methods of biodegradability and toxicity determination, modification processes to enhance biodegradability, and main applications of biodegradable polymers for agriculture, medical, and packaging. Finally, this review presents a discussion of the implications of biodegradation on the environment, the current context, and future perspectives of plastic biodegradation., State of Sao Paulo Research Foundation (FAPESP), Grant/Award Numbers: 2020/08727-0, 2017/05307-8; Food Research Center-FoRC for the financial support under FAPESP, Grant/Award Number:2013/07914-8; National Council for Scientific and Technological Development (CNPq, Brazil),Grant/Award Numbers: 309548/2021 ,429043/2018-0.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Clinical presentation and proteomic signature of patients with TANGO2 mutations

  • Mingirulli, Nadja
  • Pyle, Angela
  • Hathazi, Denisa
  • Alston, Charlotte L.
  • Kohlschmidt, Nicolai
  • O'Grady, Gina
  • Waddell, Leigh
  • Evesson, Frances
  • Cooper, Sandra B. T.
  • Turner, Christian
  • Duff, Jennifer
  • Topf, Ana
  • Yubero, Delia
  • Jou, Cristina
  • Nascimento, Andrés
  • Ortez, Carlos Ignacio
  • García Cazorla, Àngels
  • Gross, Claudia
  • O'Callaghan, Maria
  • Santra, Saikat
  • Preece, Maryanne A.
  • Champion, Michael
  • Korenev, Sergei
  • Chronopoulou, Efsthatia
  • Anirban, Majumdar
  • Pierre, Germaine
  • McArthur, Daniel
  • Thompson, Kyle
  • Navas, Placido
  • Ribes Rubió, Maria Antònia
  • Tort, Frederic
  • Schlüter, Agatha
  • Pujol Onofre, Aurora
  • Montero, Raquel
  • Sarquella Brugada, Georgia
  • Lochmüller, Hanns
  • Jiménez Mallebrera, Cecilia
  • Taylor, Robert W.
  • Artuch Iriberri, Rafael
  • Kirschner, Janbernd
  • Grünert, Sarah C.
  • Roos, Andreas
  • Horvath, Rita
Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q10 (CoQ10 ) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum-Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ10 with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Riboflavin-responsive and -non-responsive mutations in FAD synthase cause multiple Acyl-CoA dehydrogenase and combined respiratory-chain deficiency

  • Olsen, Rikke K.J.
  • Gutierrez-Rios, Purificacion
  • Barile, Maria
et al., Multiple acyl-CoA dehydrogenase deficiencies (MADDs) are a heterogeneous group of metabolic disorders with combined respiratory-chain deficiency and a neuromuscular phenotype. Despite recent advances in understanding the genetic basis of MADD, a number of cases remain unexplained. Here, we report clinically relevant variants in FLAD1, which encodes FAD synthase (FADS), as the cause of MADD and respiratory-chain dysfunction in nine individuals recruited from metabolic centers in six countries. In most individuals, we identified biallelic frameshift variants in the molybdopterin binding (MPTb) domain, located upstream of the FADS domain. Inasmuch as FADS is essential for cellular supply of FAD cofactors, the finding of biallelic frameshift variants was unexpected. Using RNA sequencing analysis combined with protein mass spectrometry, we discovered FLAD1 isoforms, which only encode the FADS domain. The existence of these isoforms might explain why affected individuals with biallelic FLAD1 frameshift variants still harbor substantial FADS activity. Another group of individuals with a milder phenotype responsive to riboflavin were shown to have single amino acid changes in the FADS domain. When produced in E. coli, these mutant FADS proteins resulted in impaired but detectable FADS activity; for one of the variant proteins, the addition of FAD significantly improved protein stability, arguing for a chaperone-like action similar to what has been reported in other riboflavin-responsive inborn errors of metabolism. In conclusion, our studies identify FLAD1 variants as a cause of potentially treatable inborn errors of metabolism manifesting with MADD and shed light on the mechanisms by which FADS ensures cellular FAD homeostasis., The study was supported by the Aarhus County Research Initiative, the Danish Council of Independent Medical Research (4004-00548 to R.K.J.O.), the John and Birthe Meyer Foundation (N.G.), the European Commission FP7-PEOPLE-ITN Mitochondrial European Educational Training Project (GA 317433 to R.H., J.A.M., and H.P.), the Neuromuscular Research Association Angela Maria Nieddu (L.V.), the Telethon Genetic BioBank (GTB12001D to E.P.), the EuroBioBank network (E.P.), the Telethon Foundation (grant GGP15041 to D.G.), the Italian Ministry of Health (GR2010–2316392 to D.G.), the Programma Operativo Nazionale “Ricerca e Competitività” 2007–2013 (01_00937 to M.B.), the European Research Council (309548 to R.H.), the UK Medical Research Council (G1000848 to R.H.), the German Bundesministerium für Bildung und Forschung (BMBF) through the German Network for Mitochondrial Disorders (mitoNET; 01GM1113C to T.M. and H.P.), the E-Rare project GENOMIT (01GM1207 to T.M. and H.P.), and the Juniorverbund in der Systemmedizin “mitOmics” (FKZ 01ZX1405C to T.B.H.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MFN2 mutations in Charcot–Marie–Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics

  • Larrea, Delfina
  • Pera, Marta
  • Gonnelli, Adriano
  • Quintana-Cabrera, Ruben
  • Akman, H. Orhan
  • Guardia-Laguarta, Cristina
  • Velasco, Kevin R.
  • Area-Gomez, Estela
  • Dal Bello, Federica
  • De Stefani, Diego
  • Horvath, Rita
  • Shy, Michael E.
  • Schon, Eric A.
  • Giacomello, Marta
Charcot–Marie–Tooth disease (CMT) type 2A is a form of peripheral neuropathy, due almost exclusively to dominant mutations in the nuclear gene encoding the mitochondrial protein mitofusin-2 (MFN2). However, there is no understanding of the relationship of clinical phenotype to genotype. MFN2 has two functions: it promotes inter-mitochondrial fusion and mediates endoplasmic reticulum (ER)–mitochondrial tethering at mitochondria-associated ER membranes (MAM). MAM regulates a number of key cellular functions, including lipid and calcium homeostasis, and mitochondrial behavior. To date, no studies have been performed to address whether mutations in MFN2 in CMT2A patient cells affect MAM function, which might provide insight into pathogenesis. Using fibroblasts from three CMT2AMFN2 patients with different mutations in MFN2, we found that some, but not all, examined aspects of ER–mitochondrial connectivity and of MAM function were indeed altered, and correlated with disease severity. Notably, however, respiratory chain function in those cells was unimpaired. Our results suggest that CMT2AMFN2 is a MAM-related disorder but is not a respiratory chain-deficiency disease. The alterations in MAM function described here could also provide insight into the pathogenesis of other forms of CMT., U.S. Department of Defense (W911F-15-1-0169 to E.A.S.); J. Willard and Alice S. Marriott Foundation (to E.A.S.); U.S. National Institutes of Health (P01-HD032062 to E.A.S. and K01-AG045335 to E.A.-G.); American Parkinson Disease Association (to C.G.-L.); Keith B Hayes Foundation and the Kassab Family (to H.O.A.); CARIPARO Starting Grant 2016 AIFbiol (to M.G.), DeBio Departmental Research Project PRID Seed 2017 (to M.G.) and Unipd STARS Consolidator (‘Featuring a new class of Interface Regulators: the mitochondria–ER spacers’ to M.G.); Wellcome Centre for Mitochondrial Research (109915/Z/15/Z and 203105/Z/16/Z to R.H.); MRC (UK; MR/N025431/1 to R.H.); European Research Council (309548 to R.H.); Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to R.H.); Newton Fund (UK/Turkey, MR/N027302/1 to R.H.). M.S. is supported in part by the Inherited Neuropathies Consortium (U54NS065712) that is a part of the NIH National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome

  • McMacken, Grace M.
  • Spendiff, Sally
  • Whittaker, Roger G.
  • O'Connor, Emily
  • Howarth, Rachel M.
  • Boczonadi, Veronika
  • Horvath, Rita
  • Slater, Clarke R.
  • Lochmüller, Hanns
The β-adrenergic agonists salbutamol and ephedrine have proven to be effective as therapies for human disorders of the neuromuscular junction, in particular many subsets of congenital myasthenic syndromes. However, the mechanisms underlying this clinical benefit are unknown and improved understanding of the effect of adrenergic signalling on the neuromuscular junction is essential to facilitate the development of more targeted therapies. Here, we investigated the effect of salbutamol treatment on the neuromuscular junction in the ColQ deficient mouse, a model of end-plate acetylcholinesterase deficiency. ColQ-/- mice received 7 weeks of daily salbutamol injection, and the effect on muscle strength and neuromuscular junction morphology was analysed. We show that salbutamol leads to a gradual improvement in muscle strength in ColQ-/- mice. In addition, the neuromuscular junctions of salbutamol treated mice showed significant improvements in several postsynaptic morphological defects, including increased synaptic area, acetylcholine receptor area and density, and extent of postjunctional folds. These changes occurred without alterations in skeletal muscle fibre size or type. These findings suggest that β-adrenergic agonists lead to functional benefit in the ColQ-/- mouse and to long-term structural changes at the neuromuscular junction. These effects are primarily at the postsynaptic membrane and may lead to enhanced neuromuscular transmission., Guarantors of Brain/Association of British Neurologists (Clinical Research Training Fellowship to G.M.); Wellcome Trust (Pathfinder Award, 201064/Z/16/Z; Investigator Award 109915/Z/15/Z to R.H.); the Medical Research Council (Confidence in Concept fund to R.H., H.L. and S.S.; MR/N025431/1 to R.H.); Canadian Institute of Health Research (PJT 162265 to S.S. and H.L.); Newton Fund UK/Turkey (MR/N027302/1 to R.H.); European Research Council (309548 to R.H.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular pathophysiology of human MICU1 deficiency

  • Kohlschmidt, Nicolai
  • Elbracht, Miriam
  • Czech, Artur
  • Häusler, Martin
  • Phan, Vietxuan
  • Töpf, Ana
  • Huang, Kai-Ting
  • Bartok, Adam
  • Eggermann, Katja
  • Zippel, Stephanie
  • Eggermann, Thomas
  • Freier, Erik
  • Groß, Claudia
  • Lochmüller, Hanns
  • Horvath, Rita
  • Hajnóczky, György
  • Weis, Joachim
  • Roos, Andreas
Aims: MICU1 encodes the gatekeeper of the mitochondrial Ca2+ uniporter, MICU1 and biallelic loss-of-function mutations cause a complex, neuromuscular disorder in children. Although the role of the protein is well understood, the precise molecular pathophysiology leading to this neuropaediatric phenotype has not been fully elucidated. Here we aimed to obtain novel insights into MICU1 pathophysiology. Methods: Molecular genetic studies along with proteomic profiling, electron-, light- and Coherent anti-Stokes Raman scattering microscopy and immuno-based studies of protein abundances and Ca2+ transport studies were employed to examine the pathophysiology of MICU1 deficiency in humans. Results: We describe two patients carrying MICU1 mutations, two nonsense (c.52C>T; p.(Arg18*) and c.553C>T; p.(Arg185*)) and an intragenic exon 2-deletion presenting with ataxia, developmental delay and early onset myopathy, clinodactyly, attention deficits, insomnia and impaired cognitive pain perception. Muscle biopsies revealed signs of dystrophy and neurogenic atrophy, severe mitochondrial perturbations, altered Golgi structure, vacuoles and altered lipid homeostasis. Comparative mitochondrial Ca2+ transport and proteomic studies on lymphoblastoid cells revealed that the [Ca2+ ] threshold and the cooperative activation of mitochondrial Ca2+ uptake were lost in MICU1-deficient cells and that 39 proteins were altered in abundance. Several of those proteins are linked to mitochondrial dysfunction and/or perturbed Ca2+ homeostasis, also impacting on regular cytoskeleton (affecting Spectrin) and Golgi architecture, as well as cellular survival mechanisms. Conclusions: Our findings (i) link dysregulation of mitochondrial Ca2+ uptake with muscle pathology (including perturbed lipid homeostasis and ER-Golgi morphology), (ii) support the concept of a functional interplay of ER-Golgi and mitochondria in lipid homeostasis and (iii) reveal the vulnerability of the cellular proteome as part of the MICU1-related pathophysiology., This study was supported by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung’ and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz-Research-Cluster (grant number: 031A360E). This work was also supported by a grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR and by an NIH grant (RO1 GM102724) to GH. The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 2012-305121 ‘Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)’. RH is a Wellcome Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Newton Fund (MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412) and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A de novo CSDE1 variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents

  • Gangfuß, Andrea
  • Lochmüller, Hanns
  • Töpf, Ana
  • O'Hehir, Emily
  • Horvath, Rita
  • Kölbel, Heike
  • Schweiger, Bernd
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
CSDE1 encodes the cytoplasmic cold shock domain-containing protein E1 (CSDE1), which is highly conserved across species and functions as an RNA-binding protein involved in translationally coupled mRNA turnover. CSDE1 displays a bidirectional role: promoting and repressing the translation of RNAs but also increasing and decreasing the abundance of RNAs. Preclinical studies highlighted an involvement of CSDE1 in different forms of cancer. Moreover, CSDE1 is highly expressed in human embryonic stem cells and plays a role in neuronal migration and differentiation. A genome-wide association study suggested CSDE1 as a potential autism-spectrum disorder risk gene. A multicenter next generation sequencing approach unraveled likely causative heterozygous variants in CSDE1 in 18 patients, identifying a new autism spectrum disorder-related syndrome consisting of autism, intellectual disability, and neurodevelopmental delay. Since then, no further patients with CSDE1 variants have been reported in the literature. Here, we report a 9.5-year-old girl from a consanguineous family of Turkish origin suffering from profound delayed speech and motor development, moderate intellectual disability, neurologic and psychiatric symptoms as well as hypoplasia of corpus callosum and mildly reduced brain volume on brain magnetic resonance imaging associated with a recurrent de novo mutation in CSDE1 (c.367C > T; p.R123*) expanding the phenotypical spectrum associated with pathogenic CSDE1 variants., Funding: Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1) and the Lily Foundation and the Evelyn Trust. Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant

  • Lochmüller, Hanns
  • Balaraju, Sunitha
  • Laurie, Steven, 1973-
  • Lochmüller, Hanns
Congenital myasthenic syndromes (CMS) are a clinically and genetically heterogeneous group of disorders caused by mutations which lead to impaired neuromuscular transmission. SLC25A1 encodes a mitochondrial citrate carrier, associated mainly with the severe neurometabolic disease combined D-2- and L-2-hydroxyglutaric aciduria (D/L-2-HGA). We previously reported a single family with a homozygous missense variant in SLC25A1 with a phenotype restricted to relatively mild CMS with intellectual disability, but to date no additional cases of this CMS subtype had been reported. Here, we performed whole exome sequencing (WES) in three additional and unrelated families presenting with CMS and mild intellectual disability to identify the underlying causative gene. The WES analysis revealed the presence of a homozygous c.740G>A; p.(Arg247Gln) missense SLC25A1 variant, the same SLC25A1 variant as identified in the original family with this phenotype. Electron microscopy of muscle from two cases revealed enlarged and accumulated mitochondria. Haplotype analysis performed in two unrelated families suggested that this variant is a result of recurrent mutation and not a founder effect. This suggests that p.(Arg247Gln) is associated with a relatively mild CMS phenotype with subtle mitochondrial abnormalities, while other variants in this gene cause more severe neurometabolic disease. In conclusion, the p.(Arg247Gln) SLC25A1 variant should be considered in patients presenting with a presynaptic CMS phenotype, particularly with accompanying intellectual disability., The project is supported by Newton fund under the governance of Academy of Medical Sciences. SB is a Newton International postdoctoral fellow (Ref no.NIF003/1002). RH was supported by the Medical Research Council (UK) [MR/N025431/1], the Wellcome Investigator fund [109915/Z/15/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the European Research Council [309548] and the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z]. RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the MRC Centre for Neuromuscular Diseases (G0601943), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council (G016354/1). HL is supported by a project grant of the Canadian Institutes of Health Research (CIHR, PJT 162265)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical presentation and proteomic signature of patients with TANGO2 mutations

  • Mingirulli, Nadja
  • Pyle, Angela
  • Hathazi, Denisa
  • Alston, Charlotte L.
  • Kohlschmidt, Nicolai
  • O'Grady, Gina
  • Waddell, Leigh
  • Evesson, Frances
  • Cooper, Sandra B. T.
  • Turner, Christian
  • Duff, Jennifer
  • Topf, Ana
  • Yubero, Delia
  • Jou, Cristina
  • Nascimento, Andrés
  • Ortez, Carlos Ignacio
  • García Cazorla, Àngels
  • Gross, Claudia
  • O'Callaghan, Maria
  • Santra, Saikat
  • Preece, Maryanne A.
  • Champion, Michael
  • Korenev, Sergei
  • Chronopoulou, Efsthatia
  • Anirban, Majumdar
  • Pierre, Germaine
  • McArthur, Daniel
  • Thompson, Kyle
  • Navas, Placido
  • Ribes Rubió, Maria Antònia
  • Tort, Frederic
  • Schlüter, Agatha
  • Pujol Onofre, Aurora
  • Montero, Raquel
  • Sarquella Brugada, Georgia
  • Lochmüller, Hanns
  • Jiménez Mallebrera, Cecilia
  • Taylor, Robert W.
  • Artuch Iriberri, Rafael
  • Kirschner, Janbernd
  • Grünert, Sarah C.
  • Roos, Andreas
  • Horvath, Rita
Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q10 (CoQ10 ) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum-Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ10 with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Severe neurodevelopmental disease caused by a homozygous TLK2 variant

  • Topf, Ana
  • Oktay, Yavuz
  • Balaraju, Sunitha
  • Yilmaz, Elmasnur
  • Sonmezler, Ece
  • Yis, Uluc
  • Laurie, Steven, 1973-
  • Thompson, Rachel
  • Roos, Andreas
  • MacArthur, Daniel G.
  • Yaramis, Ahmet
  • Güngör, Serdal
  • Lochmüller, Hanns
  • Hiz, Semra
  • Horvath, Rita
A distinct neurodevelopmental phenotype characterised mainly by mild motor and language delay and facial dysmorphism, caused by heterozygous de novo or dominant variants in the TLK2 gene has recently been described. All cases reported carried either truncating variants located throughout the gene, or missense changes principally located at the C-terminal end of the protein mostly resulting in haploinsufficiency of TLK2. Through whole exome sequencing, we identified a homozygous missense variant in TLK2 in a patient showing more severe symptoms than those previously described, including cerebellar vermis hypoplasia and West syndrome. Both parents are heterozygous for the variant and clinically unaffected highlighting that recessive variants in TLK2 can also be disease causing and may act through a different pathomechanism., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). The Broad Centre for Mendelian Genomics (UM1 HG008900) is funded by the National Human Genome Research Institute with supplemental funding provided by the National Heart, Lung, and Blood Institute under the Trans-Omics for Precision Medicine (TOPMed) programme and the National Eye Institute. Data were analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy

  • van der Knoop, Marieke M.
  • Lochmüller, Hanns
  • Houlden, Henry
Data de publicació electrònica: 04-04-2022, Pathogenic variants in A Disintegrin And Metalloproteinase (ADAM) 22, the postsynaptic cell membrane receptor for the glycoprotein leucine-rich repeat glioma-inactivated protein 1 (LGI1), have been recently associated with recessive developmental and epileptic encephalopathy. However, so far, only two affected individuals have been described and many features of this disorder are unknown. We refine the phenotype and report 19 additional individuals harboring compound heterozygous or homozygous inactivating ADAM22 variants, of whom 18 had clinical data available. Additionally, we provide follow-up data from two previously reported cases. All affected individuals exhibited infantile-onset, treatment-resistant epilepsy. Additional clinical features included moderate to profound global developmental delay/intellectual disability (20/20), hypotonia (12/20), delayed motor development (19/20). Brain MRI findings included cerebral atrophy (13/20), supported by post-mortem histological examination in patient-derived brain tissue, cerebellar vermis atrophy (5/20), and callosal hypoplasia (4/20). Functional studies in transfected cell lines confirmed the deleteriousness of all identified variants and indicated at least three distinct pathological mechanisms: defective cell membrane expression (1), impaired LGI1-binding (2), and/or impaired interaction with the postsynaptic density protein PSD-95 (3). We reveal novel clinical and molecular hallmarks of ADAM22 deficiency and provide knowledge that might inform clinical management and early diagnostics., Funding: most families were collected as part of the SYNaPS Study Group collaboration funded by the Wellcome Trust and strategic award (Synaptopathies) funding (WT093205 MA and WT104033AIA). This study was also supported by JSPS/MEXT KAKENHI (Grants 19H03331, 19K22439 and 21K19390 to Y.F., Grant 19K16269 to Y.M., and Grants 20H00459 and 20H04915 to M.F.) and Japan Agency for Medical Research and Development (21wm0525022h0001 to Y.F.); intramural funding (fortüne) from the University of Tübingen (Grant 2545-1-0) and the Ministry of Science, Research and Art Baden-Württemberg to B.V. P.S. contributed to this work within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (legge 232 del 2016). T.B.H. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 418081722, 433158657. I.S.P., V.Y.V. are supported by the Government Assignment of the Russian Ministry of Health (#121061500066-2). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). S.H. is funded by TUBITAK (Turkish Scientific and Technological Research Council) Project number 216S771. R.H. is a Wellcome Trust Investigator (109915/Z/15/Z), who received support from the Medical Research Council (UK) (MR/N025431/1 and MR/V009346/1), the European Research Council (309548), the Newton Fund (UK/Turkey, MR/N027302/1), the Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily Foundation and an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COL4A1-related autosomal recessive encephalopathy in 2 Turkish children

  • Yaramis, Ahmet
  • Lochmüller, Hanns
  • Töpf, Ana
  • Sonmezler, Ece
  • Yilmaz, Elmasnur
  • Hiz, Semra
  • Yis, Uluc
  • Gungor, Serdal
  • Polat, Ayse Ipek
  • Edem, Pinar
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Yaramis, Aysenur
  • Horvath, Rita
  • Oktay, Yavuz
OBJECTIVE: This study presents the neurologic phenotypes of 2 brothers with a novel homozygous COL4A1 mutation that was identified in a large Turkish consanguineous cohort of neurogenetic diseases. METHODS: Whole-exome sequencing and bioinformatic analysis of consanguineous families with children affected by early-onset, neurogenetic disorders was performed using the RD-Connect Genome-Phenome Analysis Platform. We also performed clinical, EEG, and neuroimaging analyses in unaffected siblings and parents. RESULTS: We have identified a homozygous missense mutation in COL4A1 (p.Gly1278Ser, NM_001845.5:c.3832G>T) in 2 siblings affected by small vessel brain disease with periventricular leukoencephalopathy and ocular defects. Presenting symptoms included mild weakness, hemiparetic gait, pyramidal findings, and seizures, whereas their intellectual and behavioral functions were normal. Both parents and 5 of the siblings (3 boys and 2 girls) were heterozygous for the variant. They did not show any clinical or laboratory signs of small vessel disease. CONCLUSIONS: COL4A1 has previously been associated with dominant small vessel disease of the brain and other organs, manifesting with high penetrance in heterozygous mutation carriers. Our findings provide evidence that COL4A1-related encephalopathy can be inherited in an autosomal recessive manner, which is important for counseling, prognosis, and treatment. Genotype-phenotype correlations remain to be established., This study was supported by the Turkish Scientific and Research Council (TUBITAK) research grant 216S771 (A. Yaramis, S. Hiz, U. Yis, S. Gungor, and Y. Oktay). R. Horvath is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and the Newton Fund (UK/Turkey, MR/N027302/1)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Metabolic shift underlies recovery in reversible infantile respiratory chain deficiency

  • Hathazi, Denisa
  • Lochmüller, Hanns
  • Horvath, Rita
Reversible infantile respiratory chain deficiency (RIRCD) is a rare mitochondrial myopathy leading to severe metabolic disturbances in infants, which recover spontaneously after 6-months of age. RIRCD is associated with the homoplasmic m.14674T>C mitochondrial DNA mutation; however, only ~ 1/100 carriers develop the disease. We studied 27 affected and 15 unaffected individuals from 19 families and found additional heterozygous mutations in nuclear genes interacting with mt-tRNAGlu including EARS2 and TRMU in the majority of affected individuals, but not in healthy carriers of m.14674T>C, supporting a digenic inheritance. Our transcriptomic and proteomic analysis of patient muscle suggests a stepwise mechanism where first, the integrated stress response associated with increased FGF21 and GDF15 expression enhances the metabolism modulated by serine biosynthesis, one carbon metabolism, TCA lipid oxidation and amino acid availability, while in the second step mTOR activation leads to increased mitochondrial biogenesis. Our data suggest that the spontaneous recovery in infants with digenic mutations may be modulated by the above described changes. Similar mechanisms may explain the variable penetrance and tissue specificity of other mtDNA mutations and highlight the potential role of amino acids in improving mitochondrial disease., RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O'Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).